Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.
Virginie WesteelWolfgang SchuetteThierry UrbanDejan RadonjicUte von WangenheimRobert M LorenceMartin ReckPublished in: PloS one (2023)
Overall, nintedanib plus weekly docetaxel was well-tolerated in patients with locally advanced or metastatic lung adenocarcinoma who progressed on first-line platinum-based chemotherapy, without loss of efficacy. DLTs were manageable.
Keyphrases
- locally advanced
- squamous cell carcinoma
- rectal cancer
- neoadjuvant chemotherapy
- idiopathic pulmonary fibrosis
- small cell lung cancer
- radiation therapy
- phase ii study
- interstitial lung disease
- open label
- phase iii
- clinical trial
- study protocol
- phase ii
- advanced non small cell lung cancer
- randomized controlled trial
- placebo controlled
- tyrosine kinase